Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum.
A membrane protein recognized by monoclonal antibody SQM1 was identified in human squamous carcinomas, including those originating in the head and neck (SqCHN), lung and cervix. Cell lines derived from SqCHN of previously untreated patients expressed high amounts of this protein. In contrast, many cell lines established from SqCHN of patients previously treated with chemotherapy and/or radiation showed diminished amounts of this SQM1 protein. The expression of SQM1 antigen was determined in several SqCHN cell lines made resistant by exposure to methotrexate (MTX) in vitro. The parent cell lines all exhibited strong binding to SQM1 antibody. The MTX-resistant sublines showed much lower membrane binding of SQM1. The lowest SQM1 reactivity was found in cell lines with high resistance to MTX and with diminished rate of MTX transport. Some highly MTX-resistant cell lines which had high levels of dihydrofolate reductase, but which retained a high rate of MTX transport, also retained high levels of SQM1 binding. Reduced SQM1 protein was also found in SqCHN cells which developed resistance to the alkylating drug cis-latinum (CDDP) and which showed reduced membrane transport of CDDP. Cell growth kinetics and non-specific antigenic shifts were not responsible for the differences in SQM1 binding between the parent cell lines and their drug-resistant sublines. The finding of a novel protein which is reduced in cells resistant to MTX and CDDP could contribute to our understanding of the basic mechanisms of drug resistance. By detecting SQM1 protein in clinical specimens, it may be possible to monitor the development of drug resistance in tumors.
Bernal
S D
SD
Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115.
Speak
J A
JA
Boeheim
K
K
Dreyfuss
A I
AI
Wright
J E
JE
Teicher
B A
BA
Rosowsky
A
A
Tsao
S W
SW
Wong
Y C
YC
D000951:Antigens, Neoplasm / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D002945:Cisplatin / Q000494:pharmacology*; D004351:Drug Resistance; D005455:Fluorescent Antibody Technique; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology*; D009247:NADH, NADPH Oxidoreductases; D009363:Neoplasm Proteins / Q000378:metabolism*; D015843:Serpins; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; C409164:NDUFB7 protein, human; D009363:Neoplasm Proteins; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D009247:NADH, NADPH Oxidoreductases; D002945:Cisplatin; D008727:Methotrexate